QuidelOrtho Corp QDEL
QuidelOrtho Corp (QDEL) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $2.7B at a -41.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.083 |
| Retained earnings / assets | -0.173 |
| EBIT / assets | -0.159 |
| Equity / liabilities | 0.499 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| QDEL | QuidelOrtho Corp | 5/9 | -0.56 | — | -1.9% |
| LNTH | Lantheus Holdings, Inc. | 4/9 | 4.61 | 30.6 | +0.5% |
| IDXX | IDEXX LABORATORIES INC /DE | 8/9 | 10.43 | 41.1 | +10.4% |
| NEOG | NEOGEN CORP | 4/9 | -0.23 | — | -2.7% |
| MYGN | MYRIAD GENETICS INC | 5/9 | -5.88 | — | -1.6% |
| NTLA | Intellia Therapeutics, Inc. | 2/9 | -6.12 | — | +16.9% |
| TKNO | Alpha Teknova, Inc. | 5/9 | -1.59 | — | +7.4% |
About QuidelOrtho Corp
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.
FAQ
Is QDEL financially healthy?
QuidelOrtho Corp's Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does QDEL pay a dividend?
No, QuidelOrtho Corp does not currently pay a dividend.
How profitable is QDEL?
In FY2025, QuidelOrtho Corp had a net margin of -41.5% and a return on equity of -58.9%.
What is the analyst price target for QDEL?
The average Wall-Street price target for QuidelOrtho Corp is $18.62, about 25.6% above the recent price, from 4 analysts.
Is QDEL a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on QuidelOrtho Corp: a Piotroski F-score of 5/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-28. Facts plus Stocktoria's own computed scores — not investment advice.